Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Covington
Daiichi Sankyo
Mallinckrodt
Merck
Healthtrust
McKinsey
McKesson
Fish and Richardson

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207311

« Back to Dashboard

NDA 207311 describes EZETIMIBE, which is a drug marketed by Alkem Labs Ltd, Amneal Pharms Co, Apotex Inc, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Ohm Labs Inc, Sandoz Inc, Teva Pharms Usa, Watson Labs Inc, Zydus Pharms Usa Inc, Watson Labs Teva, Dr Reddys Labs Sa, and Impax Labs Inc, and is included in sixteen NDAs. It is available from sixteen suppliers. Additional details are available on the EZETIMIBE profile page.

The generic ingredient in EZETIMIBE is ezetimibe; simvastatin. There are twenty-four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ezetimibe; simvastatin profile page.
Summary for 207311
Tradename:EZETIMIBE
Applicant:Ohm Labs Inc
Ingredient:ezetimibe
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 207311
Medical Subject Heading (MeSH) Categories for 207311
Suppliers and Packaging for NDA: 207311
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EZETIMIBE ezetimibe TABLET;ORAL 207311 ANDA Ohm Laboratories Inc. 51660-200 N 51660-200-05
EZETIMIBE ezetimibe TABLET;ORAL 207311 ANDA Ohm Laboratories Inc. 51660-200 N 51660-200-30

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Jun 12, 2017TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Mallinckrodt
Accenture
Moodys
Queensland Health
Federal Trade Commission
Harvard Business School
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.